DelveInsight’s “Cutaneous T-cell lymphoma Pipeline Insight 2026” report provides comprehensive insights about 22+ companies and 25+ pipeline drugs in the Cutaneous T-cell lymphoma pipeline landscape. It covers the Cutaneous T-Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cutaneous T-Cell Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead in understanding the Cutaneous T-Cell Lymphoma Treatment Landscape @ https://www.delveinsight.com/sample-request/cutaneous-t-cell-lymphoma-ctcl-pipeline-insight

Key Takeaways from the Cutaneous T-Cell Lymphoma Pipeline Report

• On May 05, 2026- University of Michigan Rogel Cancer Center announced a phase II study combining pembrolizumab and mogamulizumab in patients with advanced-stage, relapsed or refractory CTCL Each cycle will equal 6 weeks. Pembrolizumab will be administered on Day 1 of each cycle. Mogamulizumab will be administered on Day 1, 8, 15, and 22 of Cycle 1. For Cycle 2 and subsequent cycles, mogamulizumab will be administered on Day 1, 15 and 29 of each cycle. Subjects will undergo a response assessment prior to Cycle 3 and every 2 cycles thereafter.
• On May 01, 2026- Bristol-Myers Squibb initiated a phase 1/2 study is to test the safety, tolerability, efficacy, and drug levels of BMS-986369 (Golcadomide) in participants with relapsed or refractory T-cell lymphomas in Japan (GOLSEEK-3).
• DelveInsight’s Cutaneous T-Cell Lymphoma pipeline report depicts a robust space with 22+ active players working to develop 25+ pipeline therapies for Cutaneous T-Cell Lymphoma treatment.
• The leading Cutaneous T-Cell Lymphoma Companies such as Innate Pharma, Kyowa Kirin, Inc., Prescient Therapeutics, Dren Bio, Boston Immune Technologies and Therapeutics, Ono Pharmaceutical, Kainova Therapeutics, Virogen Biotechnology Inc., BioInvent International, Dialectic Therapeutics, Inc., Treeline Therapeutics, Incyte Corporation and others.
• Promising Cutaneous T-Cell Lymphoma Pipeline Therapies such as E7777, CD11301 0.03%, Panobinostat, ONTAK (denileukin difitox, DAB389IL-2), Quisinostat, 12 mg, APO866, Enzastaurin, SGX301 (synthetic hypericin), Mogamulizumab, Romidepsin (depsipeptide, FK228), and others.

Stay informed about the cutting-edge advancements in Cutaneous T-Cell Lymphoma Treatments @ Cutaneous T-Cell Lymphoma Clinical Trials Assessment

The Cutaneous T-Cell Lymphoma Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Cutaneous T-Cell Lymphoma Pipeline Report also highlights the unmet needs with respect to the Cutaneous T-Cell Lymphoma.

Cutaneous T-Cell Lymphoma Overview

Cutaneous T-Cell Lymphoma (CTCL) is a rare type of non-Hodgkin lymphoma that arises from abnormal T-lymphocytes and primarily affects the skin. The disease is typically slow progressing, although certain aggressive subtypes can extend to the blood, lymph nodes, and internal organs over time. Mycosis Fungoides is the most common form, usually presenting as slowly evolving patches or plaques, while Sézary Syndrome represents a more aggressive leukemic variant associated with widespread skin redness and severe itching.

Cutaneous T-cell lymphoma Emerging Drugs

• Lacutamab: Innate Pharma

Lacutamab (IPH4102) is a first-in-class humanized cytotoxicity-inducing antibody targeting KIR3DL2, currently being evaluated in Phase II clinical trials for cutaneous T-cell lymphoma (CTCL), a rare orphan malignancy. KIR3DL2 is an inhibitory receptor of the KIR family expressed in around 65% of CTCL patients across all subtypes, with expression rising up to 90% in aggressive forms such as Sézary syndrome. The drug remains in Phase II development for CTCL.

• KK2223: Kyowa Kirin, Inc.

KK2223 is a first-in-human investigational therapy being evaluated in Phase I clinical trials for relapsed or refractory cutaneous T-cell lymphoma (CTCL), a rare and aggressive T-cell malignancy. The study is designed to assess its safety, tolerability, pharmacokinetics, and pharmacodynamic profile in CTCL patients, including Sézary syndrome and mycosis fungoides. It is administered as an intravenous infusion under a dose-escalation and backfill design to determine the maximum tolerated dose. The trial also explores preliminary anti-tumor activity and biomarker responses in advanced T-cell lymphoma.

• ONO-4685: Ono Pharmaceuticals

ONO-4685 is an investigational anti-PD-1/CD3 bispecific antibody being developed by Ono Pharmaceutical for relapsed or refractory T-cell lymphomas, including Cutaneous T-cell Lymphoma (CTCL). The therapy is designed to bind PD-1 on malignant T cells and CD3 on T cells, thereby redirecting and activating T-cell–mediated anti-tumor activity against lymphoma cells. ONO-4685 is being evaluated in a Phase I clinical trial as a monotherapy in patients with relapsed/refractory CTCL subtypes such as mycosis fungoides (MF) and Sézary syndrome (SS), with the study assessing safety, tolerability, pharmacokinetics, and preliminary efficacy.

The Cutaneous T-Cell Lymphoma pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Cutaneous T-Cell Lymphoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cutaneous T-Cell Lymphoma Treatment.
• Cutaneous T-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Cutaneous T-Cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cutaneous T-Cell Lymphoma market.

Get a detailed analysis of the latest innovations in the Cutaneous T-Cell Lymphoma pipeline @ Cutaneous T-Cell Lymphoma Unmet Needs

Cutaneous T-Cell Lymphoma Companies

Innate Pharma, Kyowa Kirin, Inc., Prescient Therapeutics, Dren Bio, Boston Immune Technologies and Therapeutics, Ono Pharmaceutical, Kainova Therapeutics, Virogen Biotechnology Inc., BioInvent International, Dialectic Therapeutics, Inc., Treeline Therapeutics, Incyte Corporation and others

Cutaneous T-cell lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Cutaneous T-Cell Lymphoma Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in Cutaneous T-Cell Lymphoma Treatment by visiting our website @ Cutaneous T-Cell Lymphoma Market Drivers and Barriers, and Future Perspectives

Scope of the Cutaneous T-Cell Lymphoma Pipeline Report

• Coverage- Global
• Cutaneous T-Cell Lymphoma Companies- Innate Pharma, Kyowa Kirin, Inc., Prescient Therapeutics, Dren Bio, Boston Immune Technologies and Therapeutics, Ono Pharmaceutical, Kainova Therapeutics, Virogen Biotechnology Inc., BioInvent International, Dialectic Therapeutics, Inc., Treeline Therapeutics, Incyte Corporation and others.
• Cutaneous T-Cell Lymphoma Pipeline Therapies- E7777, CD11301 0.03%, Panobinostat, ONTAK (denileukin difitox, DAB389IL-2), Quisinostat, 12 mg, APO866, Enzastaurin, SGX301 (synthetic hypericin), Mogamulizumab, Romidepsin (depsipeptide, FK228), and others.
• Cutaneous T-Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Cutaneous T-Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Read the full details of Cutaneous T-Cell Lymphoma Pipeline on our website @ Cutaneous T-Cell Lymphoma Emerging Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. Cutaneous T-cell lymphoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Cutaneous T-cell lymphoma– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug Name: Company Name
9. Mid Stage Products (Phase II)
10. AFM13: Affimed GmbH
11. Early Stage Products (Phase I)
12. WUCART007: Wugen
13. Preclinical Stage Products
14. Drug Name: Company Name
15. Inactive Products
16. Cutaneous T-cell lymphoma Key Companies
17. Cutaneous T-cell lymphoma Key Products
18. Cutaneous T-cell lymphoma- Unmet Needs
19. Cutaneous T-cell lymphoma- Market Drivers and Barriers
20. Cutaneous T-cell lymphoma- Future Perspectives and Conclusion
21. Cutaneous T-cell lymphoma Analyst Views
22. Cutaneous T-cell lymphoma Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/report-store/cutaneous-t-cell-lymphoma-ctcl-pipeline-insight
Country: United States
Website: https://www.delveinsight.com/report-store/cutaneous-t-cell-lymphoma-ctcl-pipeline-insight